Do analysts recommend PLRZ or CRDL?

Cardiol Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 588.26%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, PLRZ or CRDL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is PLRZ or CRDL more profitable?

Polyrizon's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Cardiol Therapeutics N/A -229.43% -165.60%

Do analysts prefer LIXT or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, LIXT or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is LIXT or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Polyrizon N/A N/A N/A

Do analysts rate PLRZ or ETHZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PLRZ or ETHZ?

Polyrizon has higher earnings, but lower revenue than Flag Ship Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Flag Ship Acquisition $4.11M 26.27 -$6.17M -$159.65 N/A

Is PLRZ or ETHZ more profitable?

Polyrizon's return on equity of 0.00% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Flag Ship Acquisition N/A -185.71% -83.12%

Do analysts recommend PLRZ or PLYX?

Polaryx Therapeutics has a consensus price target of $8.50, indicating a potential upside of 276.11%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation & earnings, PLRZ or PLYX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Polaryx Therapeutics N/A N/A N/A -$0.05 N/A

Is PLRZ or PLYX more profitable?

Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Polaryx Therapeutics N/A N/A N/A

Do analysts rate BDTX or PLRZ?

Black Diamond Therapeutics currently has a consensus target price of $9.83, suggesting a potential upside of 443.28%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.73 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, BDTX or PLRZ?

Black Diamond Therapeutics has higher revenue and earnings than Polyrizon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics $70M 1.48 $22.37M -$0.77 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is BDTX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Polyrizon N/A N/A N/A

Polyrizon (PLRZ) Competitors

$13.26 -0.16 (-1.19%)

As of 09:50 AM Eastern

Compare

PLRZ vs. CRDL, LIXT, ETHZ, PLYX, and BDTX

Should you buy Polyrizon stock or one of its competitors? MarketBeat compares Polyrizon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Polyrizon include Cardiol Therapeutics (CRDL), Lixte Biotechnology (LIXT), Flag Ship Acquisition (ETHZ), Polaryx Therapeutics (PLYX), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Polyrizon compare to Cardiol Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Cardiol Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 588.26%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Polyrizon has a beta of -1.59, meaning that its share price is 259% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cardiol Therapeutics had 3 more articles in the media than Polyrizon. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.91 beat Cardiol Therapeutics' score of 0.34 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Positive
Cardiol Therapeutics	Neutral

Polyrizon's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Summary

Cardiol Therapeutics beats Polyrizon on 7 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Polyrizon's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Polyrizon	N/A	N/A	N/A

5.1% of Lixte Biotechnology shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lixte Biotechnology has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.59, indicating that its stock price is 259% less volatile than the broader market.

In the previous week, Lixte Biotechnology had 1 more articles in the media than Polyrizon. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.91 beat Lixte Biotechnology's score of 0.84 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Lixte Biotechnology	Positive
Polyrizon	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

Lixte Biotechnology and Polyrizon tied by winning 4 of the 8 factors compared between the two stocks.

How does Polyrizon compare to Flag Ship Acquisition?

Polyrizon (NASDAQ:PLRZ) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Polyrizon has higher earnings, but lower revenue than Flag Ship Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Flag Ship Acquisition	$4.11M	26.27	-$6.17M	-$159.65	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon has a beta of -1.59, suggesting that its share price is 259% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Polyrizon's return on equity of 0.00% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Flag Ship Acquisition	N/A	-185.71%	-83.12%

4.1% of Flag Ship Acquisition shares are held by institutional investors. 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Polyrizon's average media sentiment score of 0.91 beat Flag Ship Acquisition's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Positive
Flag Ship Acquisition	Neutral

Summary

Polyrizon and Flag Ship Acquisition tied by winning 4 of the 8 factors compared between the two stocks.

How does Polyrizon compare to Polaryx Therapeutics?

Polyrizon (NASDAQ:PLRZ) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

In the previous week, Polaryx Therapeutics had 4 more articles in the media than Polyrizon. MarketBeat recorded 4 mentions for Polaryx Therapeutics and 0 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.91 beat Polaryx Therapeutics' score of 0.23 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Positive
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has a consensus price target of $8.50, indicating a potential upside of 276.11%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats Polyrizon on 4 of the 5 factors compared between the two stocks.

How does Polyrizon compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Black Diamond Therapeutics has higher revenue and earnings than Polyrizon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.48	$22.37M	-$0.77	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Polyrizon's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Polyrizon	N/A	N/A	N/A

Black Diamond Therapeutics has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.59, meaning that its stock price is 259% less volatile than the broader market.

Black Diamond Therapeutics currently has a consensus target price of $9.83, suggesting a potential upside of 443.28%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Polyrizon. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for Polyrizon. Black Diamond Therapeutics' average media sentiment score of 1.47 beat Polyrizon's score of 0.91 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Positive
Polyrizon	Positive

Summary

Black Diamond Therapeutics beats Polyrizon on 11 of the 13 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.97M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	N/A	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.72	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.02	7.92	10.62	6.14
Net Income	-$3.34M	$23.81M	$3.60B	$331.74M
7 Day Performance	-3.63%	-1.09%	-1.26%	-1.82%
1 Month Performance	-1.19%	2.56%	1.07%	-1.45%
1 Year Performance	143.45%	42.16%	23.63%	16.32%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	0.8964 of 5 stars	$13.26 -1.2%	N/A	+121.0%	$27.58M	N/A	N/A	N/A	Gap Down
CRDL Cardiol Therapeutics	1.9273 of 5 stars	$0.99 +0.1%	$8.50 +756.0%	+3.8%	$114.44M	N/A	N/A	20
LIXT Lixte Biotechnology	0.4398 of 5 stars	$7.51 +4.2%	N/A	+85.0%	$112.80M	N/A	N/A	4	Gap Up
ETHZ Flag Ship Acquisition	N/A	$5.90 -1.0%	N/A	N/A	$112.17M	$4.11M	N/A	7	Gap Down
PLYX Polaryx Therapeutics	3.5354 of 5 stars	$2.36 -3.0%	$8.50 +260.8%	N/A	$111.84M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors

PLRZ vs. CRDL, LIXT, ETHZ, PLYX, and BDTX

How does Polyrizon compare to Cardiol Therapeutics?

Summary

How does Polyrizon compare to Lixte Biotechnology?

Summary

How does Polyrizon compare to Flag Ship Acquisition?

Summary

How does Polyrizon compare to Polaryx Therapeutics?

Summary

How does Polyrizon compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polyrizon (PLRZ) Competitors

PLRZ vs. CRDL, LIXT, ETHZ, PLYX, and BDTX

How does Polyrizon compare to Cardiol Therapeutics?

Do analysts recommend PLRZ or CRDL?

Which has more volatility & risk, PLRZ or CRDL?

Which has preferable earnings & valuation, PLRZ or CRDL?

Do institutionals & insiders hold more shares of PLRZ or CRDL?

Does the media favor PLRZ or CRDL?

Is PLRZ or CRDL more profitable?

Summary

How does Polyrizon compare to Lixte Biotechnology?

Is LIXT or PLRZ more profitable?

Do institutionals & insiders have more ownership in LIXT or PLRZ?

Which has more risk & volatility, LIXT or PLRZ?

Does the media prefer LIXT or PLRZ?

Do analysts prefer LIXT or PLRZ?

Which has higher earnings & valuation, LIXT or PLRZ?

Summary

How does Polyrizon compare to Flag Ship Acquisition?

Which has higher valuation and earnings, PLRZ or ETHZ?

Do analysts rate PLRZ or ETHZ?

Which has more risk & volatility, PLRZ or ETHZ?

Is PLRZ or ETHZ more profitable?

Do institutionals and insiders have more ownership in PLRZ or ETHZ?

Does the media refer more to PLRZ or ETHZ?

Summary

How does Polyrizon compare to Polaryx Therapeutics?

Does the media favor PLRZ or PLYX?

Do analysts recommend PLRZ or PLYX?

Which has higher valuation & earnings, PLRZ or PLYX?

Is PLRZ or PLYX more profitable?

Summary

How does Polyrizon compare to Black Diamond Therapeutics?

Which has preferable valuation & earnings, BDTX or PLRZ?

Do insiders and institutionals hold more shares of BDTX or PLRZ?

Is BDTX or PLRZ more profitable?

Which has more risk and volatility, BDTX or PLRZ?

Do analysts rate BDTX or PLRZ?

Does the media prefer BDTX or PLRZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ vs. The Competition

Polyrizon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools